No Data
Merck, Bristol-Myers Fail to Convince FDA AdCom on Wider Opdivo, Keytruda Use
Bristol-Myers Squibb Company (BMY): Among the Dividend Giants With Lowest Short Interest in 2024
Bristol Myers Squibb (BMY) Dips More Than Broader Market: What You Should Know
Bristol-Myers Squibb Options Spot-On: On September 25th, 79,506 Contracts Were Traded, With 784.28K Open Interest
FDA Casts Doubt On Use Of Merck, Bristol Myers' PD-1 Cancer Drugs For Certain Type Of Gastric Cancer Patients
Unusual Options Activity: AVTR, DG and Others Attract Market Bets, AVTR V/OI Ratio Reaches 200.0